S ketamine hcl

All solvents purchased were of analytical grade and used without further purification. S-ketamine HCl was purchased from Sigma-Aldrich (St. Louis, MO, USA; Cat. #K1884, CAS #33643-47-9. We purchased R-ketamine HCl from Cayman Chemicals (Ann Arbor, MI, USA; Cat. #16519, CAS#33795-24-3).

HEK293 cell lines expressing either the rat or human α7 nAChR (+ resistance to inhibitors of cholinesterase 3 (RIC-3)), rat α1β1δε nAChR, rat α4β2 nAChR, rat α3β4 nAChR or human 5-HT_3A receptor were developed by Bristol-Myers Squibb (Wallingford, CT, USA). The following chemicals were synthesized by Bristol-Myers Squibb: A-582941, BMS-933043, EVP-6124, NS-6740 (4-[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]carbonyl]-1,4-diazabicyclo[3.2.2]nonane), PNU-282987 (N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro-benzamide hydrochloride), TC-5619, [³H]-A585539 (³H-2,2-dimethyl-5-(6-phenyl-3-pyridazinyl)-5-aza-2-azoniabicyclo[2.2.1]heptane iodide; specific activity 71 Ci/mmol, concentration 1mCi/ml). Suppliers for other reagents were as follows: (±)epibatidine dihydrochloride hydrate (FLIPR studies), phencyclidine hydrochloride (PCP), (+)MK-801 hydrogen maleate ([5R,10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine), S(+)ketamine HCl and (-)nicotine hydrogen tartrate salt (Sigma-Aldrich, Saint Louis, Mo); methyllycaconitine citrate, (±)epibatidine (binding studies) and MDL-72222 (tropanyl 3,5-dichlorobenzoate BioTechne, Minneapolis, MN); [³H]granisetron ([³H]BRL-43694, specific activity 83.66 Ci/mmol, concentration 1 mCi/ml; Perkin Elmer, Waltham, MA).